Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.883
+0.133 (2.80%)
Nov 5, 2024, 1:16 PM EST - Market open
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 9 or 39.13% compared to the previous year.
Employees
32
Change (1Y)
9
Growth (1Y)
39.13%
Revenue / Employee
n/a
Profits / Employee
-$1,208,281
Market Cap
52.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 32 | 9 | 39.13% |
Dec 31, 2022 | 23 | -1 | -4.17% |
Dec 31, 2021 | 24 | 2 | 9.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Fortress Biotech | 186 |
Vicarious Surgical | 131 |
Aadi Bioscience | 89 |
Affimed | 76 |
Lucid Diagnostics | 70 |
Kezar Life Sciences | 58 |
OncoCyte | 46 |
SCYNEXIS | 29 |
ELTX News
- 5 days ago - Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - GlobeNewsWire
- 20 days ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire
- 7 weeks ago - Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - GlobeNewsWire
- 2 months ago - Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting - GlobeNewsWire